Abstract:Acute myeloid leukemia (AML) is a common type of adult leukemia, and its incidence increases with age, with a poor overall prognosis [ 1 ]. The incidence of AML in the USA is approximately 4.3/100 000, with a 5-year survival rate of about 24% [ 1 ]. Most AML patients experience relapse within 12 months after treatment, but the risk of relapse decreases over time [ 2 ]. According to the European LeukemiaNet (ELN) scoring system for prognosis evaluation of relapsed young AML patients (age ≤ 60), the proportion of high-risk relapsed AML patients is 66%, with 1-year and 5-year overall survival rates of 16% and 4% respectively [ 3 ]. ELN confirmed that shorter time to relapse, adverse genetic characteristics, and older age at relapse are positively correlated with poor prognosis. With current treatment methods, the complete remission rate (CR) of AML can reach 50–80%, but more than 20% of AML patients still cannot achieve CR. Furthermore, most AML patients who achieve CR will still experience relapse, leading to clinically relapsed/refractory AML [ 4 ]. In AML patients who are not suitable for intensive chemotherapy, hypomethylating agents (azacitidine and decitabine) alone or in combination with FLT3 inhibitors, IDH1/2 inhibitors, or BCL2 inhibitors are used as standard treatment regimens [ 2 ]. At present, targeted therapy combined with hypomethylating agents remains the main treatment approach in relapsed/refractory AML patients [ 5 ]. DNA methyltransferase 1 (DNMT1) is a member of the DNMT family, unlike DNMT3A and DNMT3B, which de novo synthesize DNA methylation patterns, DNMT1 is responsible for introducing methylation into the daughter strand after DNA replication [ 6 ]. Members of the DNMT family are closely associated with the progression of AML, and inhibiting the function of DNMT1 significantly reduces the methylation level of the daughter strand, thereby inhibiting the malignant phenotype of AML [ 6 ]. In AML cell and animal models, the robust loss of DNA methylation, transcriptional activation, and inhibition of cancer cell growth are induced by a reversible DNMT1-selective inhibitor that competes with the active-site loop of DNMT1 to penetrate hemi-methylated DNA between two CpG base pairs [ 7 ]. In addition, DNMT1 could be a potential synthetic lethal target in AML cases with DNMT3A mutation [ 8 ].

DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia

DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias

Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway

Dna Methyltransferases in Hematologic Malignancies

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia

Epigenetic Landscape Analysis of Lncrnas in Acute Myeloid Leukemia with DNMT3A Mutations.

DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding

Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation.

NPM1 Mutation Contributes to Hematological Dysfunction by Disrupting H3K79 Methylation

Mutant DNA Methylation Regulators Endow Hematopoietic Stem Cells with the Preleukemic Stem Cell Property, a Requisite of Leukemia Initiation and Relapse

Hdot1l Links Histone Methylation to Leukemogenesis.

Disruption of Dntp Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors Using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (Sam)-Dependent Methyltransferase Family.

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation

Loss of Dnmt3b Accelerates MLL-AF9 Leukemia Progression

Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia

DOT1L Complex Regulates Transcriptional Initiation in Human Erythroleukemic Cells

Dnmt3a Arg882 Mutation Drives Chronic Myelomonocytic Leukemia Through Disturbing Gene Expression/Dna Methylation in Hematopoietic Cells

3141 – LEUKEMIA-ASSOCIATED MUTATIONS IN DNMT3A MEDIATE SENSITIVITY TO REPLICATION STRESS INDUCED BY NUCLEOSIDE ANALOGS